Corrigendum

A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice

Chieh-Fang Cheng, Divya Sahu, Fred Tsen, Zhengwei Zhao, Jianhua Fan, Rosie Kim, Xinyi Wang, Kathryn O’Brien, Yong Li, Yuting Kuang, Mei Chen, David T. Woodley and Wei Li

Published February 1, 2012

Original citation: J. Clin. Invest. 2011;121(11):4348–4361. doi:10.1172/JCI46475.

Citation for this corrigendum: J. Clin. Invest. 2012;122(2):779. doi:10.1172/JCI62538.

In Figure 2, concentrations of the recombinant Hsp90α added to the real wounds in mice were inaccurate. The correct figure and legend appear below.

Figure 2

F-5 is superior to FDA-approved becaplermin/PDGF-BB in acute wound healing. Full-thickness skin wounds (1 cm × 1 cm) in athymic nude mice were treated (only once on day 0) with either 200 μl of 5% CMC gel (placebo) or the same volume of the gel containing an optimized concentration of a given peptide: (A) full-length, (B) F-2, (C) F-5, (D) F-6 (n = 3 mice per peptide, per experiment), or (E) becaplermin (20 μg of PDGF-BB or 8 μM). Plus signs indicate treated mice, and minus signs indicate placebo mice. The images of 1 representative experiment are shown.

The authors regret the error.